Bliss GVS Pharma Ltd (BLISSGVS)
₹693.00
Mkt cap
₹7,351 Cr
P/E ratio
53.40
P/B
6.13
Div yield
0.22%
ROE
11.80%
ROCE
16.90%
EPS (TTM)
₹12.98
Book value
₹113
52W range
128–693
Sector
Healthcare
Price history
Previous close
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
NSE BLISSGVSBSE 506197
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
0.00% from high₹693
₹128+441.83% from low₹693
Current
₹693.00
Prev close
₹693.00
Day
0.00%
Price performance
1D
0.00%
1W
+9.93%
1M
+44.44%
3M
+63.19%
6M
+219.99%
1Y
+334.10%
YTD
+325.62%
Financials
Revenue, profit & margin
P/E ratio
53.4×
BLISSGVS is 52% above the sector median of 35.1×
BLISSGVS53.4×
Sector median35.1×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 160 | 212 | 201 | 198 | 184 | 218 | 210 | 198 | 207 | 244 | 218 | 257 | 286 | |
| Expenses | 135 | 158 | 157 | 170 | 149 | 176 | 181 | 177 | 166 | 201 | 183 | 213 | 209 | |
| Operating Profit | 24 | 54 | 44 | 28 | 34 | 41 | 30 | 21 | 41 | 43 | 35 | 44 | 76 | |
| OPM % | 15% | 26% | 22% | 14% | 19% | 19% | 14% | 11% | 20% | 18% | 16% | 17% | 27% | |
| Other Income | 5 | 13 | 5 | -24 | 4 | 5 | 15 | 12 | 35 | 8 | 16 | 11 | 10 | |
| Interest | 1 | 1 | 2 | 2 | 2 | 4 | 1 | 2 | 5 | 3 | 1 | 2 | 1 | |
| Depreciation | 6 | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 9 | 10 | |
| Profit before tax | 22 | 59 | 40 | -4 | 30 | 36 | 36 | 23 | 63 | 41 | 41 | 45 | 75 | |
| Tax % | 34% | 27% | 27% | 24% | 26% | 28% | 29% | 29% | 30% | 30% | 39% | 18% | 32% | |
| Net Profit | 14 | 43 | 29 | -5 | 22 | 26 | 26 | 17 | 44 | 29 | 25 | 37 | 51 | |
| EPS in Rs | 1.41 | 4.05 | 2.64 | -0.87 | 1.97 | 2.31 | 2.26 | 1.47 | 4.08 | 2.58 | 2.20 | 3.36 | 4.72 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +4.99% · closed higher next day 1 of last 1
| Q1FY27† | |
|---|---|
| Broadcast | 12 Aug '26◦ |
| Earnings day | +4.99% |
| +1 day | +6.07% |
| +5 days | +18.51% |
| +15 days | +30.60% |
| +30 days | — |
| Filing |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202635.01%Promoter
Promoters35.01%0.35
FIIs8.07%2.38
DIIs9.46%4.42
Public47.45%1.70
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| BLISSGVS | ₹691.35 | 53.42 | 7,351 | 0.22% | 51 | +16.40% | 286 | +37.65% | 16.93% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts7
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 4 Sep - The ESOP Allotment Committee of the Company at its meeting held on today i.e. September 04, 2026 has approved the allotment of 55,250 equity shares …Post-Offer Advertisement 2 Sep - Post-offer advertisement for Anupam Rasayan’s 26% open offer in Bliss GVS Pharma; 1,669 shares acquired.Announcement under Regulation 30 (LODR)-Newspaper Publication 25 Aug - The Newspaper Publication regarding the extension of the Special Window for Re-Lodgement of Transfer Request of Physical Shares.Announcement under Regulation 30 (LODR)-Newspaper Publication 21 Aug - The Newspaper Publication regarding the publication of the advertisement for the Postal Ballot Notice.Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 20 Aug - Postal ballot seeks approval for Mr. Santosh Parab’s appointment as Non-Executive Non-Independent Director.